Want to join the conversation?
$MRK's research and development expenses for 2015 declined by 7% from last year. This was due to favorable effects of FX, expenses recognized in prior year to rise estimated fair value of liabilities for contingent consideration, lower restructuring costs, charge in the prior year related to collaboration with Bayer AG and divestiture of MCC.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.